EP1909799A1 - Oral contraception with trimegestone - Google Patents

Oral contraception with trimegestone

Info

Publication number
EP1909799A1
EP1909799A1 EP06762699A EP06762699A EP1909799A1 EP 1909799 A1 EP1909799 A1 EP 1909799A1 EP 06762699 A EP06762699 A EP 06762699A EP 06762699 A EP06762699 A EP 06762699A EP 1909799 A1 EP1909799 A1 EP 1909799A1
Authority
EP
European Patent Office
Prior art keywords
ethinyloestradiol
trimegestone
days
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06762699A
Other languages
German (de)
French (fr)
Inventor
Oliver Gloger
Heinrich Kugelmann
Maria Popova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005034498A external-priority patent/DE102005034498A1/en
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of EP1909799A1 publication Critical patent/EP1909799A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • the invention relates to a method for contraception by the administration of trimegestone.
  • the invention further relates to pharmaceutical compositions and dosage forms which contain trimegestone.
  • Trimegestone (17 ⁇ -[(S)-2-hydroxypropanoyl]-17 ⁇ -methyl-estra-4,9-dien-3-one) is a known prior art gestagen. It may be considered as a very potent progestin with regard to strong endometrial transformation effect and moderate ovulation suppression. The pharmacodynamic profile is very close to progesterone, the natural progestin. Reference may for example be made in this connection to EP-A 007 823. Combinations of trimegestone with oestrogens for contraception are described, for example, in WO 98/04246, WO 98/04265, WO 98/04268 and WO 98/04269. WO 01/37841 discloses the administration of trimegestone in combination with oestradiol for treating the symptoms of the menopause and for preventing post-menopausal osteoporosis.
  • oral contraceptive preparations comprise a gestagen in combination with an oestrogen as the hormonal active ingredients, with administration conventionally proceeding for 21-25 days in each 28-day menstrual cycle. Thereafter, either a placebo or nothing at all is administered for 3-7 days, so initiating withdrawal bleeding.
  • a contraceptive preparation should, on the one hand, provide good cycle control and, on the other hand, exhibit no or only slight side-effects.
  • Cycle control is primarily effected by the oestrogen.
  • the cycle controlling effect of the oestrogen in turn may be influenced by the gestagen and hence, the nature and the dose of the gestagen are also important factors to be taken into account.
  • Good cycle control is in particular also distinguished by the occurrence of the desired (withdrawal) bleeding, which may inter alia be characterised by
  • gestagen/ oestrogen combination is administered either at a constant dose (monophasic) or in a bi- or multiphasic regimen.
  • WO 98/04269 discloses a monophasic regimen and WO 98/04265, WO 98/04268 and WO 98/04246 disclose multiphasic regimens, with inter alia 40-500 ⁇ g of trimegestone being administered daily in combination with an oestrogen. While according to A.E. Schindler et al., Maturitas, 2003, 46, S1 , 7-16 the ovulation inhibition dose of trimegestone is 0.5 mg per day p.o., according to WO 98/04269, WO 98/04265, WO 98/04268 and WO 98/04246 the administered daily dose of trimegestone is preferably in the range from 40 to 250 ⁇ g. However, it is at least doubtful whether a daily dose of e.g. 40 ⁇ g trimegestone is sufficient in order to provide and to maintain a reliable contraceptive effect.
  • Entirely regular administration is, however, difficult to guarantee for practical reasons. It is known, for example, that a not inconsiderable proportion of women occasionally forget to take the dose intended for a particular day and only catch up on the following day. It may also happen, that the intended dose is administered in the morning on one day and not until the evening on the following day. Similar problems may also arise if the woman vomits after having taken the contraceptive, but before the dose has been completely resorbed.
  • the consequent fluctuations in plasma concentration may, as a result of the low dose of the administered active ingredients, possibly fall to values below the minimum threshold concentration which would be necessary to ensure reliable contraception. In such cases, the effectiveness of the contraception cannot always be guaranteed with a minimised active ingredient dose.
  • the fluctuations in plasma concentration may furthermore also result in premature onset of (withdrawal) bleeding (intermenstrual bleeding, for example as spotting or breakthrough bleeding).
  • trimegestone may in some women result in a plasma concentration which is above the necessary minimum concentration, but in other women, due to faster metabolisation, a higher dose would be necessary in order to ensure effective contraception.
  • the object of the invention is to provide a contraceptive method which exhibits advantages over prior art methods. Apart from ensuring effective contraception, the method should ensure good cycle control and exhibit no or at most only slight side- effects, for example no depressive mood effect and no disadvantageous effects on carbohydrate metabolism and lipid or lipoprotein levels. These properties should be relatively insensitive to irregularities in administration of the active ingredients and to intehndividual variations. This object is achieved by the subject matter of the claims.
  • trimegestone when trimegestone is administered in combination with an oestrogen for oral contraception, the ratio of gestagen to oestrogen may be varied within relatively broad limits thereby providing a reliable contraceptive effect without consequently giving rise to increased side-effects, such as for example depressive mood effect and disadvantageous effects on carbohydrate metabolism and lipid or lipoprotein levels. It has thus surprisingly been found that the dose of trimegestone may be increased within certain limits without simultaneously also having to increase the dose of the oestrogen in order to maintain the gestagen- oestrogen balance. In this way, side-effects which would otherwise accompany an elevated dose of the oestrogen are prevented.
  • the invention relates to a method for contraception comprising preferably oral administration of
  • trimegestone optionally in combination with at least one oestrogen, preferably ethinyloestradiol, or optionally in combination with two oestrogens, preferably ethinylestradiol and oestradiol, and/or optionally in combination with at least one further gestagen, and/or optionally in combination with at least one further physiologically active substance,
  • the daily dose of trimegestone is more than 500 ⁇ g.
  • the daily dose of trimegestone is in the range from more than 500 ⁇ g to less than 2,000 ⁇ g, or it is more than 2,000 ⁇ g.
  • the daily dose of trimegestone is in the range from more than 500 ⁇ g to less than 2,000 ⁇ g, or it is more than 2,000 ⁇ g.
  • trimegestone is administered in combination with at least one oestrogen at least on one, preferably on all of the at least 21 , preferably 24 successive days.
  • the oestrogen is preferably selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, oestradiol (17 ⁇ -oestradiol), oestriol, oestrone, ethinyloestradiol, hexoestrol, mestranol, methallenoestril, methyloestrenol, promestriene and conjugated oestrogens or the pharmaceutically acceptable esters thereof.
  • Ethinyloestradiol or a combination of ethinyloestradiol and oestradiol (17 ⁇ -oestradiol) are particularly preferred.
  • Preferred pharmaceutically acceptable esters of the above listed oestrogens are acetates, propionates and valerates (for example oestradiol valerate).
  • the daily dose of the oestrogen preferably corresponds to an equivalent dose of 5.0 to 55 ⁇ g, more preferably of 10 to 50 ⁇ g, still more preferably of 15 to 48 ⁇ g, most preferably of 20 to 45 ⁇ g and in particular of 22 to 40 ⁇ g of ethinyloestradiol. 20 ⁇ g or 30 ⁇ g are particularly preferred. If two or more oestrogens are used, the daily overall dose thereof preferably corresponds to the above-stated equivalent doses, the equivalent dose preferably being related to the ovulation inhibition effect of the oestrogen.
  • trimegestone in a daily dose of 1,000 to 3,000 ⁇ g is administered in combination with ethinyloestradiol in a daily dose of 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g, on 24 or 25 successive days of a 28-day menstrual cycle.
  • ethinyloestradiol is adminstered in a daily dose of 30 ⁇ 5 ⁇ g, preferably 30 ⁇ 2.5 ⁇ g, in combination with trimegestone, the daily dose of trimegestone being > 500 ⁇ g, ⁇ 625 ⁇ g, ⁇ 750 ⁇ g, 875 ⁇ g, > 1,000 ⁇ g, ⁇ 1,125 ⁇ g, ⁇ 1,250 ⁇ g, > 1,375 ⁇ g, > 1,500 ⁇ g, > 1,625 ⁇ g, ⁇ 1,750 ⁇ g, > 1,875 ⁇ g, > 2,000 ⁇ g, ⁇ 2,125 ⁇ g, > 2,250 ⁇ g, ⁇ 2,375 ⁇ g, ⁇ 2,500 ⁇ g, 2,625 ⁇ g, > 2,750 ⁇ g, > 2,875 ⁇ g, > 3,000 ⁇ g, > 3,125 ⁇ g, > 3,250 ⁇ g, ⁇ 3,375 ⁇ g, > 3,500 ⁇ g, > 3,625 ⁇
  • the weight ratio of ethinyloestradiol to trimegestone is below 1 :45.
  • the daily dose of trimegestone corresponds to an equivalent dose of norethisterone actetate in a weight ratio of ethinyloestradiol to norethisterone acetate of below 1 :45, the equivalent dose preferably being related to the ovulation inhibition efficacy of norethisterone acetate and trimegestone, respectively.
  • ethinyloestradiol is administered in a daily dose of 1.0 to 55 ⁇ g, preferably 20 ⁇ 5 or 30 ⁇ 5 ⁇ g, and/or oestradiol (17 ⁇ -oestradiol) is administered in a daily dose of 1 ,000 to 10,000 ⁇ g, preferably 1 ,000 to 5,000 ⁇ g.
  • trimegestone is administered either not together with oestradiol (17 ⁇ -oestradiol) or together with a combination of oestradiol (17 ⁇ -oestradiol) and ethinyloestradiol.
  • oestradiol (17 ⁇ -oestradiol) is thus preferably only administered when ethinyloestradiol is also administered.
  • trimegestone is administered in a daily dose of 1 ,000 to 3,000 ⁇ g in combination with ethinyloestradiol in a daily dose of 10 to 20 ⁇ g and oestradiol in a daily dose of 1 ,000 to 5,000 ⁇ g, on 24 or 25 successive days of a 28-day menstrual cycle.
  • trimegestone is administered in combination with at least one further physiologically active substance at least on one, preferably on all of the at least 21 , preferably 24 successive days.
  • said further physiologically active substance is selected from the group consisting of folic acid, folinic acid, vitamin C, vitamin B preparations, iron(ll) preparations, iron(lll) preparations, calcium preparations and magnesium preparations.
  • vitamin B preparations examples include vitamin Bi preparations, such as thiamine hydrochloride and thiamine nitrate; vitamin B 2 preparations, such as riboflavin and riboflavin-5'-phosphate; nicotinamid preparations; vitamin B 6 preparations, such as pyridoxine hydrochloride; panthotenic acid preparations, such as dexpanthenol; and vitamin Bi 2 preparations, such as cyanocobalamin and hydroxocobalamin acetate.
  • vitamin Bi preparations such as thiamine hydrochloride and thiamine nitrate
  • vitamin B 2 preparations such as riboflavin and riboflavin-5'-phosphate
  • nicotinamid preparations examples include vitamin B 6 preparations, such as pyridoxine hydrochloride; panthotenic acid preparations, such as dexpanthenol; and vitamin Bi 2 preparations, such as cyanocobalamin and hydroxocobalamin acetate.
  • iron(ll) preparations are iron(ll) sulfate, iron(ll) carbonate, iron(ll) chloride, iron(ll) tartrate, iron(ll) gluconate, iron(ll) aspartate, iron(ll) glycine sulfate, iron(ll) fumarate, iron(ll) ascorbate, iron(ll) iodate, iron(ll) succinate and ammonium iron(ll) sulfate.
  • iron(lll) preparations are iron(lll) sodium citrate, iron(lll) oxide/sucrose complex, sodium feredetate, iron(lll) hydroxide, dextriferron, iron(lll) citrate, chondroitin sulfate/iron(lll) complex, iron(lll) acetyltransferrin, iron(lll) protein succinylate and potassium/iron(lll) phosphate/citrate complex.
  • Examples of calcium preparations are calcium carbonate, calcium citrate, calcium hydrogenphosphate, calcium phosphate, calcium aspartinate, calcium bisaspartate, calcium hydrogenaspartate, calcium gluconate, calcium lactate, calcium lactogluconate, calcium glucoheptonate, calcium acetate, calcium saccharate, calcium orotate and calcium lactobionate.
  • magnesium preparations are magnesium hydrogenaspartate, magnesium L-aspartate hydrochloride, magnesium oxide, magnesium hydrogenphosphate, magnesium citrate, magnesium hydrogencitrate, magnesium sulfate, magnesium L-hydrogenglutamate, magnesium D-gluconate, magnesium orotate, mgnesium adipate and magnesium nicotinate.
  • Preferred regimens are listed in the following table, the daily dose of trimegestone being A1 , A2 or A3 and the daily dose of the at least one oestrogen, preferably ethinyloestradiol, being B:
  • the equivalent dose to ethinyloestradiol may be effected by an equivalent quantity of each suitable oestrogen, the quantity here being selected such that the oestrogenic activity corresponds to that which would be brought about by the administration of ethinyloestradiol in the stated quantity, ethinyloestradiol itself being the preferred oestrogen.
  • Two or more different oestrogens, for example ethinyloestradiol in combination with oestradiol may also be used in a quantity which corresponds overall to the stated equivalent dose, preferably being related to the ovulation inhibition effect. Suitable methods for determining the equivalent dose are known to the person skilled in the art. Trimegestone is preferably used in combination with ethinyloestradiol or in combination with ethinyloestradiol and oestradiol (17 ⁇ - oestradiol).
  • the daily dose of trimegestone and of the oestrogen is in each case constant on all days within a phase and different on two successive days of different phases.
  • Particularly preferred regimens 1', 2i ⁇ 2 2 ⁇ 3i ⁇ 3 2 ', 3 3 1 , 4-T and 4 2 ' may be found in the following table, according to which ethinyloestradiol is administered on 21-24 successive days in a daily dose of 20 ⁇ 5 ⁇ g in combination with trimegestone in daily doses A1 , A2 and A3, respectively, as defined in tables a, b, c and d supra:
  • trimegestone is not administered on all the days of the preferably 28-day menstrual cycle. Instead, it is preferred that, on the days which follow the at least 21 , preferably 24 successive days,
  • the menstrual cycle preferably lasts 28 days.
  • the menstrual cycle it is, however, also possible for the menstrual cycle to be longer than 28 days.
  • trimegestone is preferably administered on more than 28 successive days.
  • (uninterrupted) administration of trimegestone proceeds on at least 42 or 56, more preferably at least 63, still more preferably at least 84, most preferably at least 105, 112 or 120 and in particular at least 126, 140, 150, 183, 184, 189 or 365 successive days, such that it is not intended to initiate withdrawal bleeding within this period.
  • (uninterrupted) administration of trimegestone proceeds on more than 183 but less than 365 days.
  • the continuous period for which trimegestone may be administered daily may also be still longer. In principle, it is accordingly possible to administer trimegestone on all successive days over one or more years, without any withdrawal bleeding occurring.
  • trimegestone is preferably administered in a daily dose of 1 ,000 to 3,000 ⁇ g in combination with ethinyloestradiol in a daily dose of 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g on every day of said more than 28 days, e.g. more than 183 days, without interruption.
  • trimegestone is preferably administered in a daily dose of 1 ,000 to 3,000 ⁇ g in combination with ethinyloestradiol in a daily dose of 10 to 20 ⁇ g and oestradiol in a daily dose of 1 ,000 to 5,000 ⁇ g on every day of said more than 28 days, e.g. more than 183 days, without interruption.
  • the days which follow the more than 28 days preferably on the consecutive 3, 4, 5, 6 or 7 days which follow the more than 28 days,
  • trimegestone is administered in a daily dose of 1 ,000 to 3,000 ⁇ g in combination with ethinyloestradiol in a daily dose of 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g on every day of said more than 28 days, e.g. at least 84 consecutive days, without interruption, and the 7 consecutive days following said more than 28 days, ethinyloestradiol is administered in a daily dose of 5 to 10 ⁇ g in the absence of trimegestone.
  • trimegestone is administered in combination with at least one further gestagen at least on one of the at least 21 , preferably 24 successive days.
  • the further gestagen is here preferably selected from the group consisting of allyloestrenol, chlormadinone, danazol, demegestone, desogestrel, dienogest, drospirenone, dydrogesterone, ethisterone, etynodiol, gestodene, gestonorone, hydroxyprogesterone, levonorgestrel, lynoestrenol, medroxyprogesterone, medrogestone, megestrol, methyloestrenol, methylnortestosterone, nomegestrol, norethisterone, norethynodrel, norgestrel, norgestimate, progesterone, promegestone and tibolone, or the pharmaceutically acceptable
  • Preferred pharmaceutically acceptable esters of the above listed gestagens are acetates (for example chlormadinone acetate, nomegestrol acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate), caproates (for example hydroxyprogesterone caproate) and enantates (for example norethisterone enantate).
  • acetates for example chlormadinone acetate, nomegestrol acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate
  • caproates for example hydroxyprogesterone caproate
  • enantates for example norethisterone enantate
  • the daily dose of the further gestagen preferably corresponds to an equivalent dose of 100 to 5,000 ⁇ g, more preferably of 250 to 4,000 ⁇ g, still more preferably of 500 to 3,500 ⁇ g, most preferably of 750 to 3,000 ⁇ g and in particular of 1 ,000 to 2,500 ⁇ g of chlormadinone acetate, the equivalent dose preferably being related to the ovulation inhibition effect of chlormadinone acetate or the endometrial effect of chlormadinone acetate.
  • the method according to the invention is carried out for at least one menstrual cycle.
  • the method according to the invention is preferably carried out for two or more, in particular for at least 3, 4, 5 or 6 successive menstrual cycles.
  • the present invention also relates to a, preferably solid, pharmaceutical composition
  • a, preferably solid, pharmaceutical composition comprising trimegestone in a quantity of more than 500 ⁇ g, preferably at least 600 ⁇ g, still more preferably at least 700 ⁇ g, yet more preferably at least 1 ,000 ⁇ g, most preferably at least 1 ,200 ⁇ g and in particular 1 ,000 to 3,000 ⁇ g, in combination with ethinyloestradiol, preferably in a quantity of 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g.
  • the present invention also relates to a, preferably solid, pharmaceutical composition
  • a, preferably solid, pharmaceutical composition comprising trimegestone in a quantity
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising trimegestone in a quantity of more than 500 ⁇ g, preferably of at least 750 ⁇ g, still more preferably of at least 1 ,000 ⁇ g, most preferably of at least 2,000 ⁇ g and in particular of at least 3,000 ⁇ g, in combination with ethinyloestradiol in a quantity of preferably at least 5 ⁇ g, more preferably 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising trimegestone in a quantity of more than 500 ⁇ g, preferably of at least 750 ⁇ g, still more preferably of at least 1 ,000 ⁇ g, most preferably of at least 2,000 ⁇ g and in particular of at least 3,000 ⁇ g, in combination with ethinyloestradiol in a quantity of preferably at least 5 ⁇ g, more preferably 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g, and oestradiol in a quantity of preferably 1 ,000 to 10,000 ⁇ g, more preferably 1 ,000 to 5,000 ⁇ g.
  • the pharmaceutical composition according to the invention is preferably formulated for oral administration. It preferably assumes the form of (film coated) tablets, sugar coated tablets or multiparticulate form, preferably the form of microtablets, microcapsules, micropellets, accretion pellets, granules, extrudates, spheroids, beads or pellets, which may optionally be packaged in capsules or press-moulded to form (film coated) tablets. Dry-compacted formulations are also possible.
  • the present invention also relates to a dosage form comprising the pharmaceutical composition as described above, preferably for once daily, preferably oral administration.
  • the dosage form according to the invention comprises trimegestone in a quantity of more than 500 ⁇ g; preferably of at least 510 ⁇ g; more preferably of at least 525 ⁇ g, at least 1 ,000 ⁇ g, at least 1 ,500 ⁇ g or at least 2,000 ⁇ g; still more preferably of 550 to 950 ⁇ g; most preferably of 575 to 925 ⁇ g and in particular of 600 to 900 ⁇ g, wherein the dosage form is preferably selected from the group consisting of film coated tablets, sugar coated tablets and capsules.
  • the dosage form it comprises trimegestone in a quantity of ⁇ 1 ,000 ⁇ g and less than 2,000 ⁇ g or of ⁇ 2,000 ⁇ g.
  • the dosage form according to the invention may assume multiparticulate form, preferably the form of microtablets, microcapsules, micropellets, accretion pellets, granules, extrudates, spheroids, beads or pellets, optionally packaged in capsules or press-moulded to form (film coated) tablets. Dry-compacted formulations are also possible.
  • the dosage form according to the invention is selected from the group consisting of film coated tablets, sugar coated tablets and capsules and comprises the pharmaceutical composition according to the invention.
  • the pharmaceutical composition or dosage form according to the invention preferably additionally contains at least one oestrogen, preferably ethinyloestradiol.
  • the at least one oestrogen is here preferably selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, oestradiol (17 ⁇ -oestradiol), oestriol, oestrone, ethinyloestradiol, hexoestrol, mestranol, methallenoestril, methyloestrenol, promestriene and conjugated oestrogens or the pharmaceutically acceptable esters thereof.
  • Preferred pharmaceutically acceptable esters are valerates (for example oestradiol valerate).
  • the quantity of the oestrogen preferably corresponds to an equivalent dose of 5.0 to 55 ⁇ g, more preferably of 10 to 50 ⁇ g, still more preferably of 15 to 48 ⁇ g, most preferably of 20 to 45 ⁇ g and in particular of 22 to 40 ⁇ g of ethinyloestradiol, ethinyoestradiol itself being the preferred oestrogen. If two or more oestrogens are used, the overall quantity thereof preferably corresponds to the above-stated equivalent doses, which are preferably related to the ovulation inhibition effect.
  • composition or dosage form contains
  • the pharmaceutical composition or dosage form according to the invention additionally contains at least one further gestagen apart from trimegestone.
  • the further gestagen is here preferably selected from the group consisting of allyloestrenol, chlormadinone, danazol, demegestone, desogestrel, dienogest, drospirenone, dydrogesterone, ethisterone, etynodiol, gestodene, gestonorone, hydroxyprogesterone, levonorgestrel, lynoestrenol, medroxyprogesterone, medrogestone, megestrol, methyloestrenol, methylnortestosterone, nomegestrol, norethisterone, norethynodrel, norgestrel, norgestimate, progesterone, promegestone and tibolone, or the pharmaceutically acceptable esters thereof.
  • Preferred pharmaceutically acceptable esters are acetates (for example chlormadinone acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate), caproates (for example hydroxyprogesterone caproate) and enantates (for example norethisterone enantate).
  • acetates for example chlormadinone acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate
  • caproates for example hydroxyprogesterone caproate
  • enantates for example norethisterone enantate
  • the quantity of the further gestagen preferably corresponds to an equivalent dose of 100 to 5,000 ⁇ g, more preferably of 250 to 4,000 ⁇ g, still more preferably of 500 to 3,500 ⁇ g, most preferably of 750 to 3,000 ⁇ g and in particular of 1 ,000 to 2,500 ⁇ g of chlormadinone acetate, the equivalent dose preferably being related to the ovulation inhibition effect of chlormadinone acetate or the endometrial effect, i.e. endometrial transformation effect, of chlormadinone acetate.
  • the pharmaceutical composition or dosage form according to the invention contains further active ingredients, in particular at least one oestrogen (such as ethinyloestradiol) and/or a further gestagen, these are preferably present as a mixture within the same administration unit.
  • Such dosage forms may be produced with the assistance of conventional methods and auxiliary substances. Suitable auxiliary substances are known to the person skilled in the art. In this connection, reference may be made, for example, to HP. Fiedler, Lexikon der Hilfsstoffe f ⁇ r Pharmazie, Kosmetik und angrenzende füre, Editio Cantor Aulendorff, 2002; and R.C. Rowe et al., Handbook of Pharmaceutical Excipients, APhA Publications, 4 th edition, 2003 in their entirety.
  • auxiliary substances are salt formers, buffers, emulsifiers, solubilising agents (solubilisers), wetting agents, antifoaming agents, gel formers, thickeners, film formers, surfactants, binders, slip agents, lubricants, embedding agents, mould release agents, flow-control agents, disintegration accelerators (disintegrants), chelating agents, sorbents, fillers, pharmaceutical solvents, antioxidants (for example ⁇ -tocopherol), preservatives, plasticizers, flavour and odour correctives and colorants.
  • solubilising agents solubilisers
  • wetting agents wetting agents
  • antifoaming agents gel formers
  • thickeners thickeners
  • film formers film formers
  • surfactants binders
  • slip agents lubricants
  • embedding agents mould release agents
  • flow-control agents disintegration accelerators (disintegrants)
  • chelating agents sorbents
  • fillers pharmaceutical solvents
  • extenders are lactose, mannitol, calcium diphosphate, starch, microcrystalline cellulose, calcium carbonate (E170) and magnesium carbonate.
  • disintegration accelerators examples include starch, for example maize starch, potato starch, crosslinked polyvinylpyrrolidone and low substituted sodium carboxymethylcellulose.
  • binders are starch (e.g. potato starch, maize starch), gelatin, polyvinylpyrrolidone, cellulose ethers, sugars, for example sucrose and glucose syrup.
  • slip agents examples include talcum, sodium stearyl fumarate, fatty acid esters and macrogol.
  • lubricants are stearic acid, magnesium stearate, calcium stearate and zinc stearate.
  • An example of a flow-control agent is colloidal silicon dioxide.
  • Examples of pharmaceutical solvents are propylene glycol and glycerol.
  • a surfactant is polyoxyethylene/sorbitan fatty acid ester (for example Polysorbate 80).
  • colorants are indigo carmine (E132), titanium dioxide (E171 ) and quinoline yellow (E104).
  • film formers are shellac, methylcellulose, hypromellose (hydroxypropyl- methylcellulose, HPMC), hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, polyacrylates and polymethacrylates.
  • Plasticizers, such as propylene glycol and/or polyethylene glycol may additionally be contained in the film coating composition.
  • embedding agents are carnauba wax, montan glycol wax, stearic/ palmitic acid, glycerol trioleate and cetylstearyl alcohol.
  • chelating agents are citric acid, phenylalanine, sodium calcium edetate and disodium edetate (EDTA-Na 2 ).
  • iron(ll) preparations such as for example iron(ll) sulfate, iron(ll) carbonate, iron(ll) chloride, iron(ll) tartrate, iron(ll) gluconate, iron(ll) aspartate, iron(ll) glycine sulfate, iron(ll) fumarate, iron(ll) ascorbate, iron(ll) iodate, iron(ll) succinate and ammonium iron(ll) sulfate
  • iron(lll) preparations such as for example iron(lll) sodium citrate, iron(lll) oxide/sucrose complex, sodium feredetate, iron(lll) hydroxide, dextriferron, iron(lll) citrate, chondroitin sulfate/iron(lll) complex, iron(lll) acetyltransferrin, iron(lll) protein succinylate and potassium/iron(lll) phosphate/citrate complex.
  • iron(ll) preparations such as for example
  • a preparation containing iron is administered in combination with folic acid, folinic acid and/or a salt thereof.
  • the following iron preparations are particularly suitable for this embodiment: iron/amino acid complex, iron(ll) fumarate, iron(ll) sulfate, dextriferron, ammonium iron(ll) sulfate, iron(ll) glycine sulfate and iron(ll) gluconate.
  • the folic acid and the folinic acid, respectively, is here preferably present in free form or as its calcium salt.
  • folic acid, folinic acid and/or a salt thereof When folic acid, folinic acid and/or a salt thereof is administered, its daily dose is preferably within the range of from 0.1 to 7.5 mg, more preferably from 0.2 to 5.0 mg, still more preferably from 0.3 to 3.0 mg, most preferably from 0.4 to 2.5 mg and in particular from 0.5 to 2 mg.
  • particularly preferred auxiliary substances are talc, long chain fatty acids, magnesium stearate, stearic acid, calcium stearate, polyethylene glycol, palmitic acid, and hydrogenated vegetable oils, such as hydrogenated castor oil.
  • the pharmaceutical composition or dosage form according to the invention contains a buffer with a pH value in the range from 2.0 to 5.5.
  • the buffer is preferably formed by a mixture of citric acid and disodium hydrogenphosphate.
  • the pharmaceutical composition or dosage form according to the invention contains a cyclodextrin, such as ⁇ -cyclodextrin or ⁇ -cyclodextrin, preferably ⁇ -hydroxypropyl-cyclodextrin ( ⁇ -HP).
  • a cyclodextrin such as ⁇ -cyclodextrin or ⁇ -cyclodextrin, preferably ⁇ -hydroxypropyl-cyclodextrin ( ⁇ -HP).
  • the cyclodextrin forms a complex with trimegestone and/or an oestrogen, e.g. with ethinyloestradiol.
  • the pharmaceutical composition or dosage form according to the invention contains a further physiologically active substance, such as folic acid, folinic acid or a suitable derivative or salt, for example the calcium salt, vitamin C, vitamin B preparations, iron(ll) preparations, iron(lll) preparations, calcium preparations and magnesium preparations.
  • a further physiologically active substance such as folic acid, folinic acid or a suitable derivative or salt, for example the calcium salt, vitamin C, vitamin B preparations, iron(ll) preparations, iron(lll) preparations, calcium preparations and magnesium preparations.
  • the pharmaceutical composition or dosage form according to the invention contains the following auxiliary substances in the following preferred quantities (percentages are relative to the total weight of the dosage form):
  • the pharmaceutical composition or dosage form according to the invention contains the following auxiliary substances in the following preferred quantities (percentages are relative to the total weight of the dosage form):
  • composition or dosage form according to the invention may, for example, contain the following substances in the following preferred quantities:
  • Film-coated tablets may, for example, have the following composition:
  • the storage stability of the pharmaceutical composition or dosage form according to the present invention meets international standards (cf. European, Japanese and U.S. Pharmacopoeia).
  • the present invention also relates to a kit comprising at least one of the above- described dosage forms according to the invention.
  • the kit according to the invention is preferably designed for in each case once daily administration of the dosage forms contained therein.
  • the kit preferably comprises all the dosage forms containing trimegestone which are necessary for administering trimegestone for at least one menstrual cycle.
  • the kit is preferably made up such that the above-described method for contraception according to the invention may be carried out without entailing the acquisition of further dosage forms containing trimegestone which are not contained in the kit.
  • the kit preferably contains one dosage form for each day, as administration preferably proceeds once daily.
  • the kit according to the invention preferably comprises at least as many dosage forms containing trimegestone as are necessary for administering trimegestone on at least 21 , preferably 24 successive days of the 28-day menstrual cycle. If trimegestone is administered on fewer than 28 days, for the remaining days up to the end of the 28 days of the menstrual cycle, the kit according to the invention may contain either no dosage forms at all, or preparations containing iron, preparations containing folic acid, folates, folinic acid, folinates or placebos, preferably a preparation containing iron. It is necessary here for at least one of the dosage forms containing trimegestone of the kit according to the invention to be a dosage form according to the invention as described above.
  • the number of dosage forms containing trimegestone contained in the kit according to the invention is correspondingly increased, wherein preferably again at least one of the dosage forms containing trimegestone is a dosage form according to the invention as described above.
  • the kit according to the invention comprises all the dosage forms containing trimegestone which are necessary for administering trimegestone for at least two, more preferably at least three, still more preferably at least four, most preferably at least five and in particular at least six menstrual cycles.
  • the kit according to the invention is designed for mono- or multiphasic administration of trimegestone in combination with an oestrogen, preferably ethinyloestradiol.
  • the menstrual cycle is here preferably 28 days long.
  • the daily dose of trimegestone and of the oestrogen is in each case constant on all days within a phase and different on two successive days of different phases.
  • Trimegestone is preferably used in the dosage forms in combination with ethinyloestradiol or in combination with ethinyloestradiol and oestradiol (17 ⁇ - oestradiol).
  • Preferred embodiments no. 1, 2i, 22, 3i, 3 2 , 3 3 , 4i and 4 2 of the kit according to the invention comprise in total 21-25, preferably 24 dosage forms, containing trimegestone, wherein, depending on the number of phases, these contain trimegestone in doses A1 , A2, A3 and at least one oestrogen, preferably ethinyloestradiol, in dose B according to the following table:
  • a particularly preferred kit according to the invention contains all dosage forms that are necessary in order to allow for the administration of trimegestone in combination with ethinyloestradiol on 21-24 successive days of the menstrual cycle, thereby following any of regimens 1 ⁇ 2i ⁇ 2 2 ', 3i', 3 2 1 , 3 3 ⁇ 4i' and 4 2 ' as described above in connection with the method according to the invention.
  • kits according to the invention contains all dosage forms that are necessary in order to allow for the administration of trimegestone in combination with ethinyloestradiol on 21-24 successive days of the menstrual cycle, thereby following any of regimens 1", 2 ⁇ 2i ⁇ 3i", 3 2 ", 3 3 ", 4i” and 4 2 " as described above in connection with the method according to the invention.
  • kits according to the invention comprise 84 dosage forms containing 1 ,000-3,000 ⁇ g trimegestone in combination with 20 ⁇ 5 ⁇ g or 30 ⁇ 5 ⁇ g ethinyloestradiol and 7 dosage forms containing 10 ⁇ 5 ⁇ g ethinyloestradiol alone, i.e. in the absence of trimegestone.
  • Trimegestone optionally in combination with an oestrogen and/or a further gestagen, may also be taken optionally for a period of more than 28 days for therapeutic reasons, such as for example for the treatment and/or prevention of at least one of the complaints or conditions selected from the group consisting of bleeding disorders; dysmenorrhoea; conditions dependent on the menstrual cycle, such as endometriosis, polycystic ovarian syndrome (PCOS), uterus myomatosus, functional cysts, premenstrual syndrome and headaches/migraine; conditions influenced by the menstrual cycle, such as epilepsy, multiple sclerosis, diabetes mellitus, depression, schizophrenia, asthma and Parkinson's disease; and androgen-induced disorders, such as seborrhoea, acne, androgenetic alopecia and hirsutism.
  • the complaints or conditions selected from the group consisting of bleeding disorders; dysmenorrhoea; conditions dependent on the menstrual cycle, such as endometrio
  • the present invention accordingly also relates to the use of trimegestone, optionally in combination with an oestrogen (such as ethinyloestradiol) and/or a further gestagen, for the production of a medicine (e.g.
  • an oral contraceptive preferably with a dose of trimegestone of more than 500 ⁇ g and preferably less than 2,000 ⁇ g, for the treatment and/or prevention of at least one of the complaints or conditions selected from the group consisting of bleeding disorders; dysmenorrhoea; conditions dependent on the menstrual cycle, such as endometriosis, polycystic ovarian syndrome (PCOS), uterus myomatosus, functional cysts, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD) and headaches/migraine; and androgen-induced disorders, such as seborrhoea, acne, androgenetic alopecia and hirsutism.
  • the dosage forms according to the invention may be prepared by conventional processes. The following examples are not to be considered as limiting the scope of the invention:
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
  • composition a The tablets of composition a) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet, and packaged into a packaging comprising 24 hormone-containing daily units and 4 hormone-free daily units with the same composition but without hormones.
  • a hypromellose-based coating e.g. Opadry YS-1-2184 made by Colorcon
  • composition b The tablets of composition b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon) of the following composition (coating composition 2 mg per tablet).
  • a hypromellose-based coating e.g. Opadry YS-1-2184 made by Colorcon
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
  • Trimegestone particle size 90% ⁇ 50 ⁇ m
  • lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution.
  • the moist composition is forced through a
  • composition a The tablets of composition a) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet, and packaged into a packaging comprising 24 hormone-containing daily units and 4 hormone-free daily units.
  • a hypromellose-based coating e.g. Opadry YS-1-2184 made by Colorcon
  • composition b The tablets of composition b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon) of the following composition (coating composition 1 mg per tablet).
  • a hypromellose-based coating e.g. Opadry YS-1-2184 made by Colorcon
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
  • hormone-free, folic acid-containing tablets with a weight of 50 mg are produced, wherein the sodium salt of the folic acid is dissolved in 600 ml of aqueous ethanol.
  • Some tablets are produced as disclosed under a)
  • the tablets under a) and b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet.
  • a hypromellose-based coating e.g. Opadry YS-1-2184 made by Colorcon
  • 12 hormone-containing daily units produced according to a) and 12 hormone-containing daily units produced according to b) and 4 hormone-free daily units are packed in a package marked for a daily administration.
  • Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) and sodium folate are dissolved in 600 ml of ethanol.
  • Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution.
  • the moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet.
  • the dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
  • hormon-free, folic acid containing tablet having a weight of 50 mg are prepared by dissolving sodium folate in 600 ml aqueous ethanol.
  • the tablets a) and b), respectively, are coated with a coating based on hypromellose (e.g. Opadry YS-1-2184, Colorcon); coating composition 2 mg per tablet.
  • hypromellose e.g. Opadry YS-1-2184, Colorcon
  • hormone-containing daily units produced according to a) and 7 hormone-free daily units produced according to b) are packed in a package marked for a daily administration.
  • Example 6 120 tablets according to Example 1 a) are packed in a blister and marketed for daily administration on 120 successive days.
  • Example 6
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
  • the tablets are coated with a hypromellose-based coating of the following composition (coating composition 2 mg per tablet):
  • the tablets are packed into a blister containing 189 daily units and marketed for daily administration on 189 successive days.
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
  • Trimegestone particle size 90% ⁇ 50 ⁇ m
  • lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution.
  • the moist composition is forced through a
  • the tablets are coated with a hypromellose-based coating of the following composition (coating composition 2 mg per tablet):
  • the tablets are packed into a blister containing 365 daily units and are marketed for daily administration on 365 successive days.
  • Ethinyloestradiol (EE) and povidone K30 are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% ⁇ 50 ⁇ m), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
  • Trimegestone particle size 90% ⁇ 50 ⁇ m
  • lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution.
  • the moist composition is forced through a
  • the tablets are coated with a hypromellose-based coating of the following composition (coating composition 1 mg per tablet):
  • the tablets are packed into a blister containing 150 daily units and are marketed for daily administration on 150 successive days.

Abstract

The invention relates to a method for contraception comprising the administration of trimegestone in combination with ethinyloestradiol to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 µg.

Description

Oral contraception with trimegestone
The invention relates to a method for contraception by the administration of trimegestone. The invention further relates to pharmaceutical compositions and dosage forms which contain trimegestone.
Trimegestone (17β-[(S)-2-hydroxypropanoyl]-17α-methyl-estra-4,9-dien-3-one) is a known prior art gestagen. It may be considered as a very potent progestin with regard to strong endometrial transformation effect and moderate ovulation suppression. The pharmacodynamic profile is very close to progesterone, the natural progestin. Reference may for example be made in this connection to EP-A 007 823. Combinations of trimegestone with oestrogens for contraception are described, for example, in WO 98/04246, WO 98/04265, WO 98/04268 and WO 98/04269. WO 01/37841 discloses the administration of trimegestone in combination with oestradiol for treating the symptoms of the menopause and for preventing post-menopausal osteoporosis.
The majority of commercially available oral contraceptive preparations comprise a gestagen in combination with an oestrogen as the hormonal active ingredients, with administration conventionally proceeding for 21-25 days in each 28-day menstrual cycle. Thereafter, either a placebo or nothing at all is administered for 3-7 days, so initiating withdrawal bleeding.
In addition to effective contraception, a contraceptive preparation should, on the one hand, provide good cycle control and, on the other hand, exhibit no or only slight side-effects.
Cycle control is primarily effected by the oestrogen. However, the cycle controlling effect of the oestrogen in turn may be influenced by the gestagen and hence, the nature and the dose of the gestagen are also important factors to be taken into account. Good cycle control is in particular also distinguished by the occurrence of the desired (withdrawal) bleeding, which may inter alia be characterised by
- the time interval between cessation of administration of the active ingredient and the onset of bleeding,
- the duration of bleeding,
- the extent of bleeding and
- the occurrence of intermenstrual bleeding (for example spotting or breakthrough bleeding).
The most commonly reported side-effects are weight gain, nausea, variations in menstrual flow, breast changes such as tenderness, discomfort, or swelling, depression or mood disturbances, decreased sexual desire or response, and acne. Rare but serious potential effects include cardiovascular diseases, such as stroke, and an increased risk for breast cancer, liver tumors, and gallbladder disease (cf. e.g. CA. Frye, Neurology, 2006, 66(6 Suppl. 3), 29-36).
Since the introduction of oral contraceptive preparations, research has primarily focussed on the development of preparations which minimise the potential side- effects without in so doing exhibiting a reduced contraceptive action or deviating from the natural menstrual cycle of 28 days. The first generation of oral contraceptive preparations contained more gestagen and oestrogen than would per se have been necessary in order to ensure effective contraception. Disadvantageous haemostatic and metabolic changes, clinical problems and side-effects were associated with these high-dose first generation preparations. In 1978, the WHO recommended that the pharmaceutical industry should in future develop preparations with the lowest possible content of gestagen and oestrogen.
At first, the content of oestrogen was reduced in combination preparations because it was assumed that the side-effects known at that time, in particular thrombo-embolic disorders, were attributable to oestrogen. However, as it became increasingly clear that the gestagen was also associated with specific side-effects, in particular with cardiovascular complications, the content of gestagen in the combination preparations was also reduced. It was also recognised that a balance between oestrogen and gestagen may be established in order to avoid disadvantageous effects on carbohydrate metabolism and lipid or lipoprotein levels. It was subsequently found that, at a comparatively low dose of both the oestrogen and the gestagen, there is a synergistic action which inhibits ovulation.
Numerous therapeutic approaches have been developed in order to achieve the goal, while retaining contraceptive activity, of good cycle control and minimising the side-effects of the overall dose of steroids. In this connection, the gestagen/ oestrogen combination is administered either at a constant dose (monophasic) or in a bi- or multiphasic regimen.
WO 98/04269, for example, discloses a monophasic regimen and WO 98/04265, WO 98/04268 and WO 98/04246 disclose multiphasic regimens, with inter alia 40-500 μg of trimegestone being administered daily in combination with an oestrogen. While according to A.E. Schindler et al., Maturitas, 2003, 46, S1 , 7-16 the ovulation inhibition dose of trimegestone is 0.5 mg per day p.o., according to WO 98/04269, WO 98/04265, WO 98/04268 and WO 98/04246 the administered daily dose of trimegestone is preferably in the range from 40 to 250 μg. However, it is at least doubtful whether a daily dose of e.g. 40 μg trimegestone is sufficient in order to provide and to maintain a reliable contraceptive effect.
An ever greater reduction in the quantity of active ingredient cannot continue ad infinitum and may sometimes also cause new problems.
Accordingly, the problem sometimes arises with a minimised quantity of active ingredient that effective contraception and a stable menstrual cycle are more highly dependent on administration proceeding at the correct time so that a maximally constant plasma concentration of the active ingredients in the blood is maintained. Any deviations from a regular administration regimen, i.e. deviations from taking each day at the same time, should then as far as possible be avoided.
Entirely regular administration is, however, difficult to guarantee for practical reasons. It is known, for example, that a not inconsiderable proportion of women occasionally forget to take the dose intended for a particular day and only catch up on the following day. It may also happen, that the intended dose is administered in the morning on one day and not until the evening on the following day. Similar problems may also arise if the woman vomits after having taken the contraceptive, but before the dose has been completely resorbed.
The consequent fluctuations in plasma concentration may, as a result of the low dose of the administered active ingredients, possibly fall to values below the minimum threshold concentration which would be necessary to ensure reliable contraception. In such cases, the effectiveness of the contraception cannot always be guaranteed with a minimised active ingredient dose. Apart from failure of the contraceptive action, the fluctuations in plasma concentration may furthermore also result in premature onset of (withdrawal) bleeding (intermenstrual bleeding, for example as spotting or breakthrough bleeding).
It is furthermore known that the metabolisation of active ingredients in the body may vary between individuals, for example due to a genetic disposition. It is accordingly possible that a low dose of trimegestone may in some women result in a plasma concentration which is above the necessary minimum concentration, but in other women, due to faster metabolisation, a higher dose would be necessary in order to ensure effective contraception.
Apart from the effectiveness of contraception, the course of withdrawal bleeding also plays an important role. It is in principle desirable for bleeding to occur for only a short time and to be only slight in extent. This is desirable not only from the subjective standpoint of most women, but also on medical grounds. Short and light bleeding, for example, is associated with only slight loss of iron.
The object of the invention is to provide a contraceptive method which exhibits advantages over prior art methods. Apart from ensuring effective contraception, the method should ensure good cycle control and exhibit no or at most only slight side- effects, for example no depressive mood effect and no disadvantageous effects on carbohydrate metabolism and lipid or lipoprotein levels. These properties should be relatively insensitive to irregularities in administration of the active ingredients and to intehndividual variations. This object is achieved by the subject matter of the claims.
It has been surprisingly found that, when trimegestone is administered in combination with an oestrogen for oral contraception, the ratio of gestagen to oestrogen may be varied within relatively broad limits thereby providing a reliable contraceptive effect without consequently giving rise to increased side-effects, such as for example depressive mood effect and disadvantageous effects on carbohydrate metabolism and lipid or lipoprotein levels. It has thus surprisingly been found that the dose of trimegestone may be increased within certain limits without simultaneously also having to increase the dose of the oestrogen in order to maintain the gestagen- oestrogen balance. In this way, side-effects which would otherwise accompany an elevated dose of the oestrogen are prevented.
The invention relates to a method for contraception comprising preferably oral administration of
trimegestone, optionally in combination with at least one oestrogen, preferably ethinyloestradiol, or optionally in combination with two oestrogens, preferably ethinylestradiol and oestradiol, and/or optionally in combination with at least one further gestagen, and/or optionally in combination with at least one further physiologically active substance,
to a woman of child-bearing age on at least 21 , preferably 21 to 26, more preferably 22 to 25 and most preferably 23 or 24 successive days of a preferably 28-day menstrual cycle, beginning on day 1 or 5 of the menstrual cycle,
wherein on at least one, preferably at least on 2, more preferably at least on 5, still more preferably at least on 8, most preferably at least on 14 and in particular on all of the at least 21 successive days, the daily dose of trimegestone is more than 500 μg.
In preferred embodiments of the method according to the invention, on at least one of the at least 21 , preferably 24 successive days the daily dose of trimegestone is in the range from more than 500 μg to less than 2,000 μg, or it is more than 2,000 μg. Preferably, on at least one of the at least 21 , preferably 24 successive days the daily dose of trimegestone is
in the range from more than 500 μg to preferably less than 1 ,000 μg, preferably from 510 to 990 μg, more preferably from 525 to 975 μg, still more preferably from 550 to 950 μg, most preferably from 575 to 925 μg and in particular from 600 to 900 μg; or
in the range from ≥ 1 ,000 μg to preferably less than 2,000 μg, preferably from 1 ,010 to 1 ,990 μg, more preferably from 1 ,025 to 1 ,975 μg, still more preferably from 1 ,050 to 1 ,950 μg, most preferably from 1 ,075 to 1 ,925 μg and in particular from 1 ,100 to 1 ,900 μg; or
> 2,000 μg, preferably at least 2,100 μg, more preferably > 2,500 μg, still more preferably at least 3,000 μg, most preferably at least 4,000 μg and in particular at least 5,000 μg.
In a preferred embodiment of the method according to the invention, trimegestone is administered in combination with at least one oestrogen at least on one, preferably on all of the at least 21 , preferably 24 successive days. The oestrogen is preferably selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, oestradiol (17β-oestradiol), oestriol, oestrone, ethinyloestradiol, hexoestrol, mestranol, methallenoestril, methyloestrenol, promestriene and conjugated oestrogens or the pharmaceutically acceptable esters thereof. Ethinyloestradiol or a combination of ethinyloestradiol and oestradiol (17β-oestradiol) are particularly preferred. Preferred pharmaceutically acceptable esters of the above listed oestrogens are acetates, propionates and valerates (for example oestradiol valerate).
The daily dose of the oestrogen preferably corresponds to an equivalent dose of 5.0 to 55 μg, more preferably of 10 to 50 μg, still more preferably of 15 to 48 μg, most preferably of 20 to 45 μg and in particular of 22 to 40 μg of ethinyloestradiol. 20 μg or 30 μg are particularly preferred. If two or more oestrogens are used, the daily overall dose thereof preferably corresponds to the above-stated equivalent doses, the equivalent dose preferably being related to the ovulation inhibition effect of the oestrogen. Preferably, trimegestone in a daily dose of 1,000 to 3,000 μg is administered in combination with ethinyloestradiol in a daily dose of 20±5 μg or 30±5 μg, on 24 or 25 successive days of a 28-day menstrual cycle.
Particularly preferred embodiments of combinations of the daily dose X of trimegestone with the daily doses Y of ethinyloestradiol are summarised in the following table:
Trimegestone Ethinyloestradiol
1 ,000 < X < 3,000 10 μg < Y < 30 μg
1 ,000 < X < 3,000 7.5 μg≤Y≤12. 5μg
1 ,000 < X < 3,000 12.5 μg≤Y<17 •5μg
1 ,000 < X < 3,000 17.5 μg < Y < 22 •5μg
1 ,000 < X < 3,000 22.5 μg < Y < 27 •5μg
1,000 <X< 3,000 27.5 μg < Y < 32 ■5 μg
510μg≤X≤1 ,990 μg 10 μg < Y < 50 M9
510μg≤X<1 ,900 μg 12 μg < Y < 48 μg
525 μg < X ≤ 1 ,500 μg 15 μg < Y < 45 μg
525 μg < X < 975 μg 18 μg < Y < 42 μg
550 μg ≤ X < 950 μg 20 μg < Y < 40 μg
2,000 μg <X 10 μg < Y < 50 μg
2,100 μg <X 10 μg < Y < 50 μg 2,500 μg <X 10 μg < Y < 50 ug
According to a preferred embodiment of the present invention, ethinyloestradiol is adminstered in a daily dose of 30±5 μg, preferably 30±2.5 μg, in combination with trimegestone, the daily dose of trimegestone being > 500 μg, ≥ 625 μg, ≥ 750 μg, 875 μg, > 1,000 μg, ≥ 1,125 μg, ≥ 1,250 μg, > 1,375 μg, > 1,500 μg, > 1,625 μg, ≥ 1,750 μg, > 1,875 μg, > 2,000 μg, ≥ 2,125 μg, > 2,250 μg, ≥ 2,375 μg, ≥ 2,500 μg, 2,625 μg, > 2,750 μg, > 2,875 μg, > 3,000 μg, > 3,125 μg, > 3,250 μg, ≥ 3,375 μg, > 3,500 μg, > 3,625 μg, > 3,750 μg, > 3,875 μg, > 4,000 μg, > 4,125 μg, > 4,250 μg, > 4,375 μg, > 4,500 μg, > 4,625 μg, > 4,750 μg, > 4,875 μg or > 5,000 μg.
According to a prefered embodiment, the weight ratio of ethinyloestradiol to trimegestone is below 1 :45. According to another preferred embodiment, the daily dose of trimegestone corresponds to an equivalent dose of norethisterone actetate in a weight ratio of ethinyloestradiol to norethisterone acetate of below 1 :45, the equivalent dose preferably being related to the ovulation inhibition efficacy of norethisterone acetate and trimegestone, respectively.
In a particularly preferred embodiment, on at least one, preferably on all, of the at least 21 , preferably 24 successive days
ethinyloestradiol is administered in a daily dose of 1.0 to 55 μg, preferably 20±5 or 30±5 μg, and/or oestradiol (17β-oestradiol) is administered in a daily dose of 1 ,000 to 10,000 μg, preferably 1 ,000 to 5,000 μg.
In another particularly preferred embodiment on at least one, preferably on all, of the at least 21 , preferably 24 successive days trimegestone is administered either not together with oestradiol (17β-oestradiol) or together with a combination of oestradiol (17β-oestradiol) and ethinyloestradiol.
According to this embodiment, oestradiol (17β-oestradiol) is thus preferably only administered when ethinyloestradiol is also administered.
In a particularly preferred embodiment of the method according to the invention, on none of the at least 21 , preferably 24 successive days is an oestrogen administered without trimegestone being administered.
Preferably, trimegestone is administered in a daily dose of 1 ,000 to 3,000 μg in combination with ethinyloestradiol in a daily dose of 10 to 20 μg and oestradiol in a daily dose of 1 ,000 to 5,000 μg, on 24 or 25 successive days of a 28-day menstrual cycle.
Particularly preferred embodiments of combinations of the daily dose X of trimegestone with the daily doses Y of ethinyloestradiol and the daily dose Z of oestradiol (17β-oestradiol) are summarised in the following table:
In a preferred embodiment of the method according to the invention, trimegestone is administered in combination with at least one further physiologically active substance at least on one, preferably on all of the at least 21 , preferably 24 successive days. Preferably, said further physiologically active substance is selected from the group consisting of folic acid, folinic acid, vitamin C, vitamin B preparations, iron(ll) preparations, iron(lll) preparations, calcium preparations and magnesium preparations.
Examples of vitamin B preparations are vitamin Bi preparations, such as thiamine hydrochloride and thiamine nitrate; vitamin B2 preparations, such as riboflavin and riboflavin-5'-phosphate; nicotinamid preparations; vitamin B6 preparations, such as pyridoxine hydrochloride; panthotenic acid preparations, such as dexpanthenol; and vitamin Bi2 preparations, such as cyanocobalamin and hydroxocobalamin acetate.
Examples of iron(ll) preparations are iron(ll) sulfate, iron(ll) carbonate, iron(ll) chloride, iron(ll) tartrate, iron(ll) gluconate, iron(ll) aspartate, iron(ll) glycine sulfate, iron(ll) fumarate, iron(ll) ascorbate, iron(ll) iodate, iron(ll) succinate and ammonium iron(ll) sulfate.
Examples of iron(lll) preparations are iron(lll) sodium citrate, iron(lll) oxide/sucrose complex, sodium feredetate, iron(lll) hydroxide, dextriferron, iron(lll) citrate, chondroitin sulfate/iron(lll) complex, iron(lll) acetyltransferrin, iron(lll) protein succinylate and potassium/iron(lll) phosphate/citrate complex.
Examples of calcium preparations are calcium carbonate, calcium citrate, calcium hydrogenphosphate, calcium phosphate, calcium aspartinate, calcium bisaspartate, calcium hydrogenaspartate, calcium gluconate, calcium lactate, calcium lactogluconate, calcium glucoheptonate, calcium acetate, calcium saccharate, calcium orotate and calcium lactobionate.
Examples of magnesium preparations are magnesium hydrogenaspartate, magnesium L-aspartate hydrochloride, magnesium oxide, magnesium hydrogenphosphate, magnesium citrate, magnesium hydrogencitrate, magnesium sulfate, magnesium L-hydrogenglutamate, magnesium D-gluconate, magnesium orotate, mgnesium adipate and magnesium nicotinate.
In a preferred embodiment of the method according to the invention, the daily dose of trimegestone is identical on each of the at least 21, more preferably at least 22, still more preferably at least 23, most preferably at least 24 and in particular at least 25 successive days (= monophasic regimen), wherein administration preferably proceeds in each case in combination with at least one oestrogen, preferably 20+5 μg ethinyloestradiol or 30±5 μg ethinyloestradiol.
In another preferred embodiment of the method according to the invention, the at least 21 , more preferably at least 22, still more preferably at least 23, most preferably at least 24 and in particular at least 25 successive days are divided into two, three or more groups of days, wherein the daily dose of trimegestone is identical on all the days within a group, but the daily dose of trimegestone is different on successive days of different groups (= multiphasic regimen), and wherein administration preferably proceeds in each case in combination with at least one oestrogen, preferably ethinyloestradiol. Preferred regimens are listed in the following table, the daily dose of trimegestone being A1 , A2 or A3 and the daily dose of the at least one oestrogen, preferably ethinyloestradiol, being B:
The particular ranges of values of the doses for the particular combinations of A1 , A2, A3 and B for each one of these embodiments no. 1 , 21f 22, 3i, 32, 33, 4i and 42 may be found in the following tables a, b, c and d, the dose B of the at least one oestrogen being stated as the equivalent dose to ethinyloestradiol:
or
or
or
The equivalent dose to ethinyloestradiol may be effected by an equivalent quantity of each suitable oestrogen, the quantity here being selected such that the oestrogenic activity corresponds to that which would be brought about by the administration of ethinyloestradiol in the stated quantity, ethinyloestradiol itself being the preferred oestrogen. Two or more different oestrogens, for example ethinyloestradiol in combination with oestradiol, may also be used in a quantity which corresponds overall to the stated equivalent dose, preferably being related to the ovulation inhibition effect. Suitable methods for determining the equivalent dose are known to the person skilled in the art. Trimegestone is preferably used in combination with ethinyloestradiol or in combination with ethinyloestradiol and oestradiol (17β- oestradiol).
In the bi-, tri- and tetraphasic regimens, the daily dose of trimegestone and of the oestrogen is in each case constant on all days within a phase and different on two successive days of different phases.
Particularly preferred regimens 1', 2i\ 22\ 3i\ 32', 33 1, 4-T and 42' may be found in the following table, according to which ethinyloestradiol is administered on 21-24 successive days in a daily dose of 20±5 μg in combination with trimegestone in daily doses A1 , A2 and A3, respectively, as defined in tables a, b, c and d supra:
Further particularly preferred regimens 1", 2i", 22", 3Λ 32 11, 33", 4r and 42" may be found in the following table, according to which ethinyloestradiol is administered on 21-24 successive days in a daily dose of 30±5 μg in combination with trimegestone in daily doses A1 , A2 and A3, respectively, as defined in tables a, b, c and d supra:
In a preferred embodiment of the method according to the invention, trimegestone is not administered on all the days of the preferably 28-day menstrual cycle. Instead, it is preferred that, on the days which follow the at least 21 , preferably 24 successive days,
- a placebo,
- a pharmaceutically acceptable preparation containing iron,
- a preparation containing folic acid, folinic acid and/or a salt thereof, or - a preparation containing an oestrogen, preferably ethinylestradiol, preferably in a daily dose corresponding to an equivalent dose of ≤ 10 μg of ethinyloestradiol is administered;
- or nothing at all is administered.
In this manner, it is ensured that the menstrual cycle is terminated by the withdrawal bleeding, such that a new menstrual cycle may begin. The menstrual cycle preferably lasts 28 days.
According to another preferred embodiment of the method according to the invention, it is, however, also possible for the menstrual cycle to be longer than 28 days. This may be achieved according to the invention, by the cessation of trimegestone (and optionally at least one oestrogen and/or at least one further gestagen) not occurring until a later point in time, such that the withdrawal bleeding also does not occur until a later point in time and thus the menstrual cycle also does not end until a later point in time. In this embodiment, trimegestone is preferably administered on more than 28 successive days.
In this embodiment, (uninterrupted) administration of trimegestone proceeds on at least 42 or 56, more preferably at least 63, still more preferably at least 84, most preferably at least 105, 112 or 120 and in particular at least 126, 140, 150, 183, 184, 189 or 365 successive days, such that it is not intended to initiate withdrawal bleeding within this period. According to a preferred embodiment, (uninterrupted) administration of trimegestone proceeds on more than 183 but less than 365 days. According to the invention, the continuous period for which trimegestone may be administered daily may also be still longer. In principle, it is accordingly possible to administer trimegestone on all successive days over one or more years, without any withdrawal bleeding occurring.
When the menstrual cycle is extended to more than 28 days, e.g. more than 183 days, trimegestone is preferably administered in a daily dose of 1 ,000 to 3,000 μg in combination with ethinyloestradiol in a daily dose of 20±5 μg or 30±5 μg on every day of said more than 28 days, e.g. more than 183 days, without interruption. Alternatively, trimegestone is preferably administered in a daily dose of 1 ,000 to 3,000 μg in combination with ethinyloestradiol in a daily dose of 10 to 20 μg and oestradiol in a daily dose of 1 ,000 to 5,000 μg on every day of said more than 28 days, e.g. more than 183 days, without interruption.
Preferably, on the days which follow the more than 28 days, preferably on the consecutive 3, 4, 5, 6 or 7 days which follow the more than 28 days,
- a placebo,
- a pharmaceutically acceptable preparation containing iron,
- a preparation containing folic acid, folinic acid and/or a salt thereof, or
- a preparation containing an oestrogen, preferably ethinyloestradiol, preferably in a daily dose corresponding to an equivalent dose of ≤ 10 μg of ethinyloestradiol is administered;
- or nothing at all is administered.
In a preferred embodiment of the method according to the invention, trimegestone is administered in a daily dose of 1 ,000 to 3,000 μg in combination with ethinyloestradiol in a daily dose of 20±5 μg or 30±5 μg on every day of said more than 28 days, e.g. at least 84 consecutive days, without interruption, and the 7 consecutive days following said more than 28 days, ethinyloestradiol is administered in a daily dose of 5 to 10 μg in the absence of trimegestone.
In a preferred embodiment of the method according to the invention, trimegestone is administered in combination with at least one further gestagen at least on one of the at least 21 , preferably 24 successive days. The further gestagen is here preferably selected from the group consisting of allyloestrenol, chlormadinone, danazol, demegestone, desogestrel, dienogest, drospirenone, dydrogesterone, ethisterone, etynodiol, gestodene, gestonorone, hydroxyprogesterone, levonorgestrel, lynoestrenol, medroxyprogesterone, medrogestone, megestrol, methyloestrenol, methylnortestosterone, nomegestrol, norethisterone, norethynodrel, norgestrel, norgestimate, progesterone, promegestone and tibolone, or the pharmaceutically acceptable esters thereof. Preferred pharmaceutically acceptable esters of the above listed gestagens are acetates (for example chlormadinone acetate, nomegestrol acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate), caproates (for example hydroxyprogesterone caproate) and enantates (for example norethisterone enantate).
The daily dose of the further gestagen preferably corresponds to an equivalent dose of 100 to 5,000 μg, more preferably of 250 to 4,000 μg, still more preferably of 500 to 3,500 μg, most preferably of 750 to 3,000 μg and in particular of 1 ,000 to 2,500 μg of chlormadinone acetate, the equivalent dose preferably being related to the ovulation inhibition effect of chlormadinone acetate or the endometrial effect of chlormadinone acetate.
The method according to the invention is carried out for at least one menstrual cycle. The method according to the invention is preferably carried out for two or more, in particular for at least 3, 4, 5 or 6 successive menstrual cycles.
The present invention also relates to a, preferably solid, pharmaceutical composition comprising trimegestone in a quantity of more than 500 μg, preferably at least 600 μg, still more preferably at least 700 μg, yet more preferably at least 1 ,000 μg, most preferably at least 1 ,200 μg and in particular 1 ,000 to 3,000 μg, in combination with ethinyloestradiol, preferably in a quantity of 20±5 μg or 30±5 μg.
The present invention also relates to a, preferably solid, pharmaceutical composition comprising trimegestone in a quantity
of more than 500 μg and preferably less than 1 ,000 μg, preferably of 510 to 990 μg, more preferably of 525 to 975 μg, still more preferably of 550 to 950 μg, most preferably of 575 to 925 μg and in particular of 600 to 900 μg; or
of > 11 ,,000000 μμgg a \ nd preferably less than 2,000 μg, preferably of 1 ,010 to 1 ,990 μg, more ϊ pprreeffeerraabbly , of 1 ,025 to 1 ,975 μg, still more preferably of 1 ,050 to 1 ,950 μg, most t pprreeffeerraabbllyy ooff 1 ,075 to 1 ,925 μg and in particular of 1 ,100 to 1 ,900 μg; or
of ≥ 2,000 μg, preferably at least 2,100 μg, more preferably more than 2,500 μg, still more preferably at least 3,000 μg, most preferably at least 4,000 μg and in particular at least 5,000 μg. The present invention also relates to a pharmaceutical composition comprising trimegestone in a quantity of more than 500 μg, preferably of at least 750 μg, still more preferably of at least 1 ,000 μg, most preferably of at least 2,000 μg and in particular of at least 3,000 μg, in combination with ethinyloestradiol in a quantity of preferably at least 5 μg, more preferably 20±5 μg or 30±5 μg.
The present invention also relates to a pharmaceutical composition comprising trimegestone in a quantity of more than 500 μg, preferably of at least 750 μg, still more preferably of at least 1 ,000 μg, most preferably of at least 2,000 μg and in particular of at least 3,000 μg, in combination with ethinyloestradiol in a quantity of preferably at least 5 μg, more preferably 20±5 μg or 30±5 μg, and oestradiol in a quantity of preferably 1 ,000 to 10,000 μg, more preferably 1 ,000 to 5,000 μg.
The pharmaceutical composition according to the invention is preferably formulated for oral administration. It preferably assumes the form of (film coated) tablets, sugar coated tablets or multiparticulate form, preferably the form of microtablets, microcapsules, micropellets, accretion pellets, granules, extrudates, spheroids, beads or pellets, which may optionally be packaged in capsules or press-moulded to form (film coated) tablets. Dry-compacted formulations are also possible.
The present invention also relates to a dosage form comprising the pharmaceutical composition as described above, preferably for once daily, preferably oral administration.
The dosage form according to the invention comprises trimegestone in a quantity of more than 500 μg; preferably of at least 510 μg; more preferably of at least 525 μg, at least 1 ,000 μg, at least 1 ,500 μg or at least 2,000 μg; still more preferably of 550 to 950 μg; most preferably of 575 to 925 μg and in particular of 600 to 900 μg, wherein the dosage form is preferably selected from the group consisting of film coated tablets, sugar coated tablets and capsules.
In a preferred embodiment of the dosage form it comprises trimegestone in a quantity of ≥ 1 ,000 μg and less than 2,000 μg or of ≥ 2,000 μg. The dosage form according to the invention may assume multiparticulate form, preferably the form of microtablets, microcapsules, micropellets, accretion pellets, granules, extrudates, spheroids, beads or pellets, optionally packaged in capsules or press-moulded to form (film coated) tablets. Dry-compacted formulations are also possible.
In a preferred embodiment, the dosage form according to the invention is selected from the group consisting of film coated tablets, sugar coated tablets and capsules and comprises the pharmaceutical composition according to the invention.
The preferred embodiments described below relate both to the pharmaceutical composition according to the invention and to the dosage form according to the invention.
The pharmaceutical composition or dosage form according to the invention preferably additionally contains at least one oestrogen, preferably ethinyloestradiol. The at least one oestrogen is here preferably selected from the group consisting of chlorotrianisene, dienestrol, diethylstilbestrol, oestradiol (17β-oestradiol), oestriol, oestrone, ethinyloestradiol, hexoestrol, mestranol, methallenoestril, methyloestrenol, promestriene and conjugated oestrogens or the pharmaceutically acceptable esters thereof. Preferred pharmaceutically acceptable esters are valerates (for example oestradiol valerate).
The quantity of the oestrogen preferably corresponds to an equivalent dose of 5.0 to 55 μg, more preferably of 10 to 50 μg, still more preferably of 15 to 48 μg, most preferably of 20 to 45 μg and in particular of 22 to 40 μg of ethinyloestradiol, ethinyoestradiol itself being the preferred oestrogen. If two or more oestrogens are used, the overall quantity thereof preferably corresponds to the above-stated equivalent doses, which are preferably related to the ovulation inhibition effect.
In a preferred embodiment of the pharmaceutical composition or dosage form according to the invention, said composition or dosage form contains
- either no oestradiol (17β-oestradiol) or
- oestradiol (17β-oestradiol) in combination with ethinyloestradiol. In a preferred embodiment, the pharmaceutical composition or dosage form according to the invention additionally contains at least one further gestagen apart from trimegestone. The further gestagen is here preferably selected from the group consisting of allyloestrenol, chlormadinone, danazol, demegestone, desogestrel, dienogest, drospirenone, dydrogesterone, ethisterone, etynodiol, gestodene, gestonorone, hydroxyprogesterone, levonorgestrel, lynoestrenol, medroxyprogesterone, medrogestone, megestrol, methyloestrenol, methylnortestosterone, nomegestrol, norethisterone, norethynodrel, norgestrel, norgestimate, progesterone, promegestone and tibolone, or the pharmaceutically acceptable esters thereof. Preferred pharmaceutically acceptable esters are acetates (for example chlormadinone acetate, medroxyprogesterone acetate, megestrol acetate, norethisterone acetate), caproates (for example hydroxyprogesterone caproate) and enantates (for example norethisterone enantate).
The quantity of the further gestagen preferably corresponds to an equivalent dose of 100 to 5,000 μg, more preferably of 250 to 4,000 μg, still more preferably of 500 to 3,500 μg, most preferably of 750 to 3,000 μg and in particular of 1 ,000 to 2,500 μg of chlormadinone acetate, the equivalent dose preferably being related to the ovulation inhibition effect of chlormadinone acetate or the endometrial effect, i.e. endometrial transformation effect, of chlormadinone acetate.
If, apart from trimegestone, the pharmaceutical composition or dosage form according to the invention contains further active ingredients, in particular at least one oestrogen (such as ethinyloestradiol) and/or a further gestagen, these are preferably present as a mixture within the same administration unit. Such dosage forms may be produced with the assistance of conventional methods and auxiliary substances. Suitable auxiliary substances are known to the person skilled in the art. In this connection, reference may be made, for example, to HP. Fiedler, Lexikon der Hilfsstoffe fϋr Pharmazie, Kosmetik und angrenzende Gebiete, Editio Cantor Aulendorff, 2002; and R.C. Rowe et al., Handbook of Pharmaceutical Excipients, APhA Publications, 4th edition, 2003 in their entirety.
Examples of auxiliary substances are salt formers, buffers, emulsifiers, solubilising agents (solubilisers), wetting agents, antifoaming agents, gel formers, thickeners, film formers, surfactants, binders, slip agents, lubricants, embedding agents, mould release agents, flow-control agents, disintegration accelerators (disintegrants), chelating agents, sorbents, fillers, pharmaceutical solvents, antioxidants (for example α-tocopherol), preservatives, plasticizers, flavour and odour correctives and colorants.
Examples of extenders are lactose, mannitol, calcium diphosphate, starch, microcrystalline cellulose, calcium carbonate (E170) and magnesium carbonate.
Examples of disintegration accelerators (disintegrants) are starch, for example maize starch, potato starch, crosslinked polyvinylpyrrolidone and low substituted sodium carboxymethylcellulose.
Examples of binders are starch (e.g. potato starch, maize starch), gelatin, polyvinylpyrrolidone, cellulose ethers, sugars, for example sucrose and glucose syrup.
Examples of slip agents are talcum, sodium stearyl fumarate, fatty acid esters and macrogol.
Examples of lubricants are stearic acid, magnesium stearate, calcium stearate and zinc stearate.
An example of a flow-control agent is colloidal silicon dioxide.
Examples of pharmaceutical solvents are propylene glycol and glycerol.
One example of a surfactant is polyoxyethylene/sorbitan fatty acid ester (for example Polysorbate 80).
Examples of colorants are indigo carmine (E132), titanium dioxide (E171 ) and quinoline yellow (E104). Examples of film formers are shellac, methylcellulose, hypromellose (hydroxypropyl- methylcellulose, HPMC), hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, polyacrylates and polymethacrylates. Plasticizers, such as propylene glycol and/or polyethylene glycol may additionally be contained in the film coating composition.
Examples of embedding agents are carnauba wax, montan glycol wax, stearic/ palmitic acid, glycerol trioleate and cetylstearyl alcohol.
Examples of chelating agents are citric acid, phenylalanine, sodium calcium edetate and disodium edetate (EDTA-Na2).
Examples of preparations containing iron are iron(ll) preparations, such as for example iron(ll) sulfate, iron(ll) carbonate, iron(ll) chloride, iron(ll) tartrate, iron(ll) gluconate, iron(ll) aspartate, iron(ll) glycine sulfate, iron(ll) fumarate, iron(ll) ascorbate, iron(ll) iodate, iron(ll) succinate and ammonium iron(ll) sulfate; and iron(lll) preparations, such as for example iron(lll) sodium citrate, iron(lll) oxide/sucrose complex, sodium feredetate, iron(lll) hydroxide, dextriferron, iron(lll) citrate, chondroitin sulfate/iron(lll) complex, iron(lll) acetyltransferrin, iron(lll) protein succinylate and potassium/iron(lll) phosphate/citrate complex.
In a particularly preferred embodiment, a preparation containing iron is administered in combination with folic acid, folinic acid and/or a salt thereof. The following iron preparations are particularly suitable for this embodiment: iron/amino acid complex, iron(ll) fumarate, iron(ll) sulfate, dextriferron, ammonium iron(ll) sulfate, iron(ll) glycine sulfate and iron(ll) gluconate. The folic acid and the folinic acid, respectively, is here preferably present in free form or as its calcium salt.
When folic acid, folinic acid and/or a salt thereof is administered, its daily dose is preferably within the range of from 0.1 to 7.5 mg, more preferably from 0.2 to 5.0 mg, still more preferably from 0.3 to 3.0 mg, most preferably from 0.4 to 2.5 mg and in particular from 0.5 to 2 mg. Examples of particularly preferred auxiliary substances are talc, long chain fatty acids, magnesium stearate, stearic acid, calcium stearate, polyethylene glycol, palmitic acid, and hydrogenated vegetable oils, such as hydrogenated castor oil.
In a preferred embodiment, the pharmaceutical composition or dosage form according to the invention contains a buffer with a pH value in the range from 2.0 to 5.5. The buffer is preferably formed by a mixture of citric acid and disodium hydrogenphosphate.
In a preferred embodiment, the pharmaceutical composition or dosage form according to the invention contains a cyclodextrin, such as β-cyclodextrin or γ-cyclodextrin, preferably β-hydroxypropyl-cyclodextrin (β-HP). Preferably, the cyclodextrin forms a complex with trimegestone and/or an oestrogen, e.g. with ethinyloestradiol.
In a preferred embodiment, apart from trimegestone and optionally at least one oestrogen and/or at least one further gestagen, the pharmaceutical composition or dosage form according to the invention contains a further physiologically active substance, such as folic acid, folinic acid or a suitable derivative or salt, for example the calcium salt, vitamin C, vitamin B preparations, iron(ll) preparations, iron(lll) preparations, calcium preparations and magnesium preparations.
In a preferred embodiment, apart from trimegestone and optionally at least one oestrogen and/or at least one further gestagen, the pharmaceutical composition or dosage form according to the invention contains the following auxiliary substances in the following preferred quantities (percentages are relative to the total weight of the dosage form):
In another preferred embodiment, apart from trimegestone and optionally at least one oestrogen and/or at least one further gestagen, the pharmaceutical composition or dosage form according to the invention contains the following auxiliary substances in the following preferred quantities (percentages are relative to the total weight of the dosage form):
The pharmaceutical composition or dosage form according to the invention may, for example, contain the following substances in the following preferred quantities:
Film-coated tablets may, for example, have the following composition:
The storage stability of the pharmaceutical composition or dosage form according to the present invention meets international standards (cf. European, Japanese and U.S. Pharmacopoeia).
The present invention also relates to a kit comprising at least one of the above- described dosage forms according to the invention.
The kit according to the invention is preferably designed for in each case once daily administration of the dosage forms contained therein.
The kit preferably comprises all the dosage forms containing trimegestone which are necessary for administering trimegestone for at least one menstrual cycle. The kit is preferably made up such that the above-described method for contraception according to the invention may be carried out without entailing the acquisition of further dosage forms containing trimegestone which are not contained in the kit. The kit preferably contains one dosage form for each day, as administration preferably proceeds once daily.
If the menstrual cycle is 28 days long, the kit according to the invention preferably comprises at least as many dosage forms containing trimegestone as are necessary for administering trimegestone on at least 21 , preferably 24 successive days of the 28-day menstrual cycle. If trimegestone is administered on fewer than 28 days, for the remaining days up to the end of the 28 days of the menstrual cycle, the kit according to the invention may contain either no dosage forms at all, or preparations containing iron, preparations containing folic acid, folates, folinic acid, folinates or placebos, preferably a preparation containing iron. It is necessary here for at least one of the dosage forms containing trimegestone of the kit according to the invention to be a dosage form according to the invention as described above.
If the menstrual cycle is extended, i.e. is more than 28 days long, the number of dosage forms containing trimegestone contained in the kit according to the invention is correspondingly increased, wherein preferably again at least one of the dosage forms containing trimegestone is a dosage form according to the invention as described above.
In a preferred embodiment, the kit according to the invention comprises all the dosage forms containing trimegestone which are necessary for administering trimegestone for at least two, more preferably at least three, still more preferably at least four, most preferably at least five and in particular at least six menstrual cycles.
In a preferred embodiment, the kit according to the invention is designed for mono- or multiphasic administration of trimegestone in combination with an oestrogen, preferably ethinyloestradiol. The menstrual cycle is here preferably 28 days long. In the bi-, tri- and tetraphasic regimens, the daily dose of trimegestone and of the oestrogen is in each case constant on all days within a phase and different on two successive days of different phases.
Trimegestone is preferably used in the dosage forms in combination with ethinyloestradiol or in combination with ethinyloestradiol and oestradiol (17β- oestradiol).
Preferred embodiments no. 1, 2i, 22, 3i, 32, 33, 4i and 42 of the kit according to the invention comprise in total 21-25, preferably 24 dosage forms, containing trimegestone, wherein, depending on the number of phases, these contain trimegestone in doses A1 , A2, A3 and at least one oestrogen, preferably ethinyloestradiol, in dose B according to the following table:
The particular ranges of values of the doses for the particular combinations of A1 , A2, A3 and B for each one of these embodiments no. 1 , 2i, 22, 3i, 32, 33, 4i and 42 may be found in the following tables, the dose B of the at least one oestrogen being stated as the equivalent dose to ethinyloestradiol:
or or
or
A particularly preferred kit according to the invention contains all dosage forms that are necessary in order to allow for the administration of trimegestone in combination with ethinyloestradiol on 21-24 successive days of the menstrual cycle, thereby following any of regimens 1\ 2i\ 22', 3i', 32 1, 33\ 4i' and 42' as described above in connection with the method according to the invention. Another particularly preferred kit according to the invention contains all dosage forms that are necessary in order to allow for the administration of trimegestone in combination with ethinyloestradiol on 21-24 successive days of the menstrual cycle, thereby following any of regimens 1", 2Λ 2i\ 3i", 32", 33", 4i" and 42" as described above in connection with the method according to the invention.
Further preferred embodiments of the kit according to the invention comprise 84 dosage forms containing 1 ,000-3,000 μg trimegestone in combination with 20±5 μg or 30±5 μg ethinyloestradiol and 7 dosage forms containing 10±5 μg ethinyloestradiol alone, i.e. in the absence of trimegestone.
Trimegestone, optionally in combination with an oestrogen and/or a further gestagen, may also be taken optionally for a period of more than 28 days for therapeutic reasons, such as for example for the treatment and/or prevention of at least one of the complaints or conditions selected from the group consisting of bleeding disorders; dysmenorrhoea; conditions dependent on the menstrual cycle, such as endometriosis, polycystic ovarian syndrome (PCOS), uterus myomatosus, functional cysts, premenstrual syndrome and headaches/migraine; conditions influenced by the menstrual cycle, such as epilepsy, multiple sclerosis, diabetes mellitus, depression, schizophrenia, asthma and Parkinson's disease; and androgen-induced disorders, such as seborrhoea, acne, androgenetic alopecia and hirsutism.
The present invention accordingly also relates to the use of trimegestone, optionally in combination with an oestrogen (such as ethinyloestradiol) and/or a further gestagen, for the production of a medicine (e.g. an oral contraceptive), preferably with a dose of trimegestone of more than 500 μg and preferably less than 2,000 μg, for the treatment and/or prevention of at least one of the complaints or conditions selected from the group consisting of bleeding disorders; dysmenorrhoea; conditions dependent on the menstrual cycle, such as endometriosis, polycystic ovarian syndrome (PCOS), uterus myomatosus, functional cysts, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD) and headaches/migraine; and androgen-induced disorders, such as seborrhoea, acne, androgenetic alopecia and hirsutism. The dosage forms according to the invention may be prepared by conventional processes. The following examples are not to be considered as limiting the scope of the invention:
Example 1 :
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
The tablets of composition a) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet, and packaged into a packaging comprising 24 hormone-containing daily units and 4 hormone-free daily units with the same composition but without hormones.
The tablets of composition b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon) of the following composition (coating composition 2 mg per tablet).
24 hormone-containing tablets and 4 hormone free tablets, each as daily dosage unit, are packed into one packaging.
Example 2:
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
The tablets of composition a) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet, and packaged into a packaging comprising 24 hormone-containing daily units and 4 hormone-free daily units.
The tablets of composition b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon) of the following composition (coating composition 1 mg per tablet).
24 hormone-containing tablets and 4 hormone free tablets, each as daily dosage unit, are packed into one packaging.
Example 3:
2-phase contraceptive
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
b) Composition of the 2. phase
As indicated under a), hormone-free, folic acid-containing tablets with a weight of 50 mg are produced, wherein the sodium salt of the folic acid is dissolved in 600 ml of aqueous ethanol.
Some tablets are produced as disclosed under a)
The tablets under a) and b) are coated with a hypromellose-based coating (e.g. Opadry YS-1-2184 made by Colorcon), coating composition 2 mg per tablet. 12 hormone-containing daily units produced according to a) and 12 hormone-containing daily units produced according to b) and 4 hormone-free daily units are packed in a package marked for a daily administration. Example 4:
a) Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) and sodium folate are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
b) As set forth under a), hormon-free, folic acid containing tablet having a weight of 50 mg are prepared by dissolving sodium folate in 600 ml aqueous ethanol.
The tablets a) and b), respectively, are coated with a coating based on hypromellose (e.g. Opadry YS-1-2184, Colorcon); coating composition 2 mg per tablet.
21 hormone-containing daily units produced according to a) and 7 hormone-free daily units produced according to b) are packed in a package marked for a daily administration.
Example 5:
120 tablets according to Example 1 a) are packed in a blister and marketed for daily administration on 120 successive days. Example 6:
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 600 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and colloidal silicon dioxide and pressed on a tablet press with 5 mm punches into tablets with a weight of 50 mg.
The tablets are coated with a hypromellose-based coating of the following composition (coating composition 2 mg per tablet):
The tablets are packed into a blister containing 189 daily units and marketed for daily administration on 189 successive days.
Example 7:
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
The tablets are coated with a hypromellose-based coating of the following composition (coating composition 2 mg per tablet):
The tablets are packed into a blister containing 365 daily units and are marketed for daily administration on 365 successive days.
Example 8:
Ethinyloestradiol (EE) and povidone K30 (polyvinylpyrrolidone) are dissolved in 950 ml of ethanol. Trimegestone (particle size 90% <50μm), lactose and maize starch are mixed in a mixer/pelletiser (Diosna P25) for 5 mins and then moistened thoroughly and mixed with the ethanolic EE/PVP solution. The moist composition is forced through a 3 mm screen and dried in a vacuum drying cabinet. The dried granular product is disagglomerated through a 0.6 mm screen, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets with a weight of 80 mg.
The tablets are coated with a hypromellose-based coating of the following composition (coating composition 1 mg per tablet):
The tablets are packed into a blister containing 150 daily units and are marketed for daily administration on 150 successive days.

Claims

Claims:
1. A method for contraception comprising the administration of trimegestone in combination with ethinyloestradiol to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 μg-
2. The method according to claim 1 , wherein at least on one of the at least 21 successive days trimegestone is administered together with a combination of ethinyloestradiol and oestradiol.
3. The method according to claim 1 or 2, wherein the daily dose of ethinyloestradiol or of the combination of ethinyloestradiol and oestradiol corresponds to an equivalent dose of 5.0 to 55 μg of ethinyloestradiol.
4. The method according to any of the preceding claims, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is
- in the range from more than 500 μg to less than 2,000 μg; or
- more than 2,000 μg.
5. The method according to any of the preceding claims, wherein administration proceeds orally.
6. The method according to any of the preceding claims, wherein the menstrual cycle is 28 days long or longer than 28 days.
7. The method according to any of the preceding claims, wherein the daily dose of trimegestone is identical on each of the at least 21 successive days.
8. The method according to any of the preceding claims, wherein trimegestone is not administered on all the days of the 28-day menstrual cycle and that, on the days which follow the least 21 successive days, a placebo is administered, a preparation containing iron is administered, a preparation containing folic acid, folinic acid and/or a salt thereof is administered, a preparation containing an oestrogen, preferably ethinyloestradiol, is administered, or nothing at all is administered.
9. The method according to any of the preceding claims, which is carried out for least 6 successive menstrual cycles.
10. A pharmaceutical composition comprising trimegestone in a quantity of more than 500 μg in combination with ethinyloestradiol.
11. The composition according to claim 10, which contains a combination of ethinyloestradiol and oestradiol.
12. The composition according to claim 10 or 11 , wherein the quantity of ethinyloestradiol or of the combination of ethinyloestradiol and oestradiol corresponds to an equivalent dose of 5.0 to 55 μg of ethinyloestradiol.
13. The composition according to any of claims 10 to 12, additionally containing one or more auxiliary substances independently selected from the group comprising salt formers, buffers, emulsifiers, solubilisers, wetting agents, antifoaming agents, gel formers, thickeners, film formers, surfactants, binders, slip agents, lubricants, embedding agents, mould release agents, flow-control agents, disintegrants, chelating agents, sorbents, fillers, pharmaceutical solvents, antioxidants, preservatives, plasticizers, flavour and odour correctives and colorants.
14. The composition according to any of claims 10 to 13, for contraception.
15. A dosage form comprising the pharmaceutical composition according to any of claims 10 to 14, wherein the dosage form is selected from the group consisting of film coated tablets, sugar coated tablets and capsules.
16. A kit comprising at least one composition or dosage form according to any of claims 10 to 15.
17. The kit according to claim 16, which comprises in total 21 -25 dosage forms for once daily administration on 21-25 successive days, each of which contains ethinyloestradiol or a combination of ethinyloestradiol and oestradiol in a quantity corresponding to an equivalent dose of 5.0 to 55 μg of ethinyloestradiol and trimegestone in a quantity of more than 500 μg.
18. The kit according to claim 16, which comprises in total more than 28 dosage forms for once daily administration on successive days, at least one of which dosage forms contains ethinyloestradiol or a combination of ethinyloestradiol and oestradiol in a quantity corresponding to an equivalent dose of 5.0 to 55 μg of ethinyloestradiol and trimegestone in a quantity of more than 500 μg.
19. The kit according to claim 18, which comprises at least 84 dosage forms for once daily administration on at least 84 successive days, each of which dosage forms contains ethinyloestradiol or a combination of ethinyloestradiol and oestradiol in a quantity corresponding to an equivalent dose of 5.0 to 55 μg of ethinyloestradiol and trimegestone in a quantity of more than 500 μg.
20. The kit according to claim 19, which further comprises at least 7 dosage forms for once daily administration on 7 successive days, each of which dosage forms contains ethinyloestradiol in a quantity of 5.0 to 15 μg in the absence of trimegestone.
EP06762699A 2005-07-20 2006-07-19 Oral contraception with trimegestone Withdrawn EP1909799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005034498A DE102005034498A1 (en) 2005-07-20 2005-07-20 Oral contraception with Trimegeston
US11/348,545 US20070021396A1 (en) 2005-07-20 2006-02-06 Oral contraception with trimegestone
PCT/EP2006/007103 WO2007009769A1 (en) 2005-07-20 2006-07-19 Oral contraception with trimegestone

Publications (1)

Publication Number Publication Date
EP1909799A1 true EP1909799A1 (en) 2008-04-16

Family

ID=37075980

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06762699A Withdrawn EP1909799A1 (en) 2005-07-20 2006-07-19 Oral contraception with trimegestone

Country Status (6)

Country Link
EP (1) EP1909799A1 (en)
KR (1) KR20080031435A (en)
AR (1) AR056674A1 (en)
AU (1) AU2006271920A1 (en)
CA (1) CA2615427A1 (en)
WO (1) WO2007009769A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3888597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
FR2801218B1 (en) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc PHARMACEUTICAL COMPOSITIONS COMPRISING TRIMEGESTONE, THEIR PREPARATION METHODS AND THE PRIMARY PACKAGING CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007009769A1 *

Also Published As

Publication number Publication date
CA2615427A1 (en) 2007-01-25
WO2007009769A1 (en) 2007-01-25
AR056674A1 (en) 2007-10-17
AU2006271920A1 (en) 2007-01-25
KR20080031435A (en) 2008-04-08

Similar Documents

Publication Publication Date Title
US20120028936A1 (en) Oral contraception with trimegestone
US9375437B2 (en) Progesterone containing oral dosage forms and kits
EP1380301B1 (en) Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive
EP1265616B1 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
AU726091B2 (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US20130172300A1 (en) New hormonal composition and its use
US9278072B2 (en) Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate
JP2000515888A (en) Birth control pills
AU759925B2 (en) Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
JP2005530791A (en) Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
JP5484646B2 (en) New contraceptives and methods for their preparation
JP2000515889A (en) Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
WO2007009769A1 (en) Oral contraception with trimegestone
JP2005530790A (en) Trimegestone and estrogen for treating postmenopausal disorders
JP2005527577A (en) Hormone replacement therapy
KR20240040774A (en) Oral contraception using only progestogens
MXPA99000801A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
MXPA99000883A (en) Oral contraceptive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: POPOVA, MARIA

Inventor name: KUGELMANN, HEINRICH

Inventor name: GLOGER, OLIVER

Inventor name: TAMARA PFAFF

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120401

Country of ref document: HK

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20080220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120401

Country of ref document: HK